Fast movers • Alerts • Momentum
10% OFF with SAVE10
Charts • Watchlists • Multi-broker tools
Built for active traders
Biotech catalyst, news and analysis PDUFA tracker
Biotech catalyst, news and analysis PDUFA tracker
English Italiano RARE DISEASES · HAE · EARNINGS · FRANCHISE EXPANSION BioCryst after the transition: why BCRX is no longer just an ORLADEYO story, and why the next leg depends on execution BioCryst is not the same company the market…
SELLAS enters 2026 in a stronger position than it did only a few months ago. The company now has a better-funded balance sheet, a pivotal Phase 3 program that remains the center of gravity for the story, and a second clinical asset that is beginning to matter in a more serious way. That does not make the risk disappear. It simply means the equity story is richer, more credible and more demanding than before.
Planet Labs did not rally simply because it posted a good quarter. The market reacted because the company finally delivered a set of numbers strong enough to support a much larger narrative: Planet is no longer being framed only as a satellite-imagery vendor, but as a possible strategic geospatial infrastructure platform sitting at the intersection of sovereign data, defense demand, satellite services and AI-enabled analytics.
Intuitive Machines did not just report a mixed quarter. It effectively asked the market to stop thinking of LUNR as a single-mission lunar name and start treating it as a much larger, post-acquisition space infrastructure company built around manufacturing scale, defense programs, GEO communications, civil-space work, and eventually higher-margin network services. That is why these earnings matter. They were less about the quarter just reported and much more about whether investors are willing to believe the company can support a near-billion-dollar 2026 revenue target only a few weeks after absorbing Lanteris.
This is the continuation of the March SATL work, updated after the March 18 Merlin announcement and the March 19 fourth-quarter and full-year 2025 results. The key point is that these were not just ordinary earnings. Taken together, the two releases tried to reposition Satellogic from a small Earth observation operator into a daily global monitoring platform with sovereign, defense and persistent intelligence relevance.
FULC trades on NASDAQ. The stock has benefited from positive Phase 1b PIONEER data announced in late February 2026, which showed robust HbF induction at the 20 mg dose. Current valuation reflects pre-commercialization risk and the clinical timeline for the registration-enabling trial expected in H2 2026.
Cardiff Oncology has a fresh scientific talking point after announcing preclinical AACR 2026 data around onvansertib in therapy-resistant HER2-low breast cancer models. That headline matters because it expands the mechanistic narrative around the asset. But it does not change the center of gravity of the story. The main valuation engine is still onvansertib in first-line RAS-mutated metastatic colorectal cancer, the company’s cash runway into 2027, and management’s ability to rebuild credibility after the January leadership shock.
Spectral AI is one of those very small companies where the story looks simple on the surface and much more complicated once you open the hood. The company is trying to bring its DeepView burn-imaging platform through the FDA while using non-dilutive government support to fund part of the journey. The setup is interesting because it combines a real clinical problem, a potentially differentiated imaging workflow, and a government countermeasure angle. The catch is that this is still a micro-cap name with execution risk, regulatory risk, and financing risk that cannot be ignored.
ProKidney’s FY 2025 release did not deliver a dramatic twist, and that is exactly why it matters. Investors were not looking for revenue, because there is none. They were not looking for normal operating leverage, because this is still a pre-commercial biotech. What they needed to see was whether the company could still credibly defend the bridge from today’s balance sheet to the one milestone that truly matters, the Q2 2027 Phase 3 eGFR-slope readout in PROACT 1. For now, the answer remains yes.
SeaStar Medical goes into its March 25, 2026 earnings date with a story that is more credible medically than it was a few months ago, but not yet more comfortable financially. That distinction matters. In ultra-small medtech and biotech names, better clinical framing can improve perception, but it does not automatically repair a pressured capital structure. SeaStar’s recent updates created a more solid pediatric narrative around QUELIMMUNE, yet the company still faces the far more difficult question of whether that narrative can become durable adoption, durable funding and a less fragile 2026 outlook.
Geron’s latest earnings did not kill the bullish case and did not fully validate it either. What they did was more useful: they forced the story into a more serious phase, where commercial consistency, spending discipline and the coming IMpactMF readout matter more than launch excitement.
Protalix BioTherapeutics (PLX) reported fiscal 2025 results on March 18, 2026, with $51.8 million in revenues from selling goods, $52.7 million in total revenues, and a net loss of $6.6 million. The most important near-term development was not just the annual print itself, but the combination of that print with the European Commission approval of the every-four-weeks dosing regimen for Elfabrio, which triggered a $25 million milestone payment from Chiesi.
I deliberately waited at least one full day before writing this piece. Not to stall, but to look at the March 17, 2026 Complete Response Letter with a colder head, outside the immediate chaos of the tape. What follows is not a quick reaction article. It is a long-form reconstruction of how Aldeyra reached a third rejection in dry eye disease, why that matters far beyond one bad headline, where management deserves a tougher standard, and whether any credible path still exists for reproxalap in DED.
Kosmos Energy is one of those companies that can look dramatically different depending on the lens used. If the lens is geology and resource base, there is real substance here: Ghana remains a meaningful production engine, GTA has moved from long-promised concept into actual LNG production, and the company still retains additional development and exploration optionality. If the lens is capital structure, however, the picture is much less forgiving. High debt, prior operational disappointments, start-up cost inflation, and the need to actively manage maturities have made KOS a much harder story for equity investors than a simple “oil up, stock up” thesis.
Ovid Therapeutics is a New York-based biopharmaceutical company focused on small-molecule medicines for brain disorders driven by impaired inhibitory signaling and neuronal hyperexcitability. The current story is built around two mechanistic pillars: OV329, a next-generation GABA-AT inhibitor for refractory epilepsies, and OV4071, a first-in-class oral KCC2 direct activator for psychosis-related and broader neuropsychiatric indications.
What makes Ovid more interesting now than a few quarters ago is not just pipeline breadth, but the combination of fresh clinical support, a much stronger balance sheet, and a clearer 18–24 month cadence of milestones. On March 18, 2026, the company reported new 7 mg OV329 safety and PK data, expanded OV329 into tuberous sclerosis complex seizures and infantile spasms, confirmed Australian clearance for OV4071 Phase 1 work, and paired those updates with a new $60.0 million private placement. That package materially changed the near-term risk profile versus the leaner cash position seen in 2025.
Artelo is one of those names where two truths live side by side and both matter. The first truth is that this is not an empty shell. The pipeline is real, there are multiple shots on goal, and at least two of the programs have enough substance to justify serious attention from specialist biotech traders. ART27.13 has generated actual human data in cancer-related anorexia and now has a new ophthalmology expansion angle in glaucoma or ocular hypertension. ART26.12 has crossed the line into human testing with a completed single-ascending-dose study. ART12.11, while earlier, has regulatory progress and intellectual-property support that make it more than just a speculative line item.
Executive view. Today’s Navy ALRRM award matters, but not because the dollar amount alone changes the company overnight. What matters is that the award fits into a sequence that has become hard to ignore: first the AFRL HANGTIME work, then the missile propulsion subsystem contract, then the post-acquisition repositioning around GuideTech and defense manufacturing, and now a Navy near-hypersonic missile development award. Put differently, PDYN is no longer just trying to sell an autonomy story. It is trying to become a more complete defense-and-industrial platform where software, avionics, manufacturing, propulsion and program access all reinforce each other.
Quick take. This is a meaningful story update, not a fundamental de-risking event. ZenaTech says it is developing a low-cost, single-use autonomous interceptor drone called Interceptor P-1 for the broader ZenaDrone counter-UAS platform. The logic is clear: defeat cheap hostile drones with cheaper, faster, more scalable interceptors instead of relying only on high-cost conventional air-defense responses. That makes conceptual sense. What still matters more, however, is the gap between concept and proof: this remains a development-stage defense product announcement, not a disclosed contract, not a production milestone, and not a booked revenue line.
EN IT Ondas, Evolution How ONDS is trying to become a multi-domain defense platform in 2026 — and why the story now looks both more coherent and more demanding than it did just a few months ago. Ticker: ONDS Focus:…
GLSI is exactly the kind of name that can look much cleaner in a press release than it does in real portfolio construction. The company has one lead asset, one pivotal clinical thesis, limited cash, ongoing need for financing, and a story that can produce violent stock reactions because the float is relatively small and the clinical promise is easy to narrate. That is why the most useful way to rebuild the article in the new format is to put the scientific signal and the financing reality in the same frame from the first page.